|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-3-12
|
|
pubmed:abstractText |
The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years. Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-10561319,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-10685660,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-11161227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-14767273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-15681528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-17215529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-17215530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-17327610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-17470865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-18054825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-18073219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-18653228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-3203132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20163744-9626229
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:AnastasiouIoannisI,
pubmed-author:AndreadisCharalambosC,
pubmed-author:BamiasAristotelisA,
pubmed-author:ChristodoulouChristosC,
pubmed-author:DafniUraniaU,
pubmed-author:DimopoulosMeletios AMA,
pubmed-author:FountzilasGeorgeG,
pubmed-author:KaradimouAlexandraA,
pubmed-author:KontovinisLoukasL,
pubmed-author:LainakisGeorgeG,
pubmed-author:LampakiSofiaS,
pubmed-author:MalettouLiaL,
pubmed-author:PapandreouChristosC,
pubmed-author:PapazisisKostasK,
pubmed-author:RaziEvangeliaE,
pubmed-author:SkolarikosAndreasA,
pubmed-author:StravodimosKostasK,
pubmed-author:SyrigosKostasK,
pubmed-author:TimotheadouEleniE,
pubmed-author:XanthakisIoannisI
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
45
|
|
pubmed:meshHeading |
pubmed-meshheading:20163744-Adult,
pubmed-meshheading:20163744-Aged,
pubmed-meshheading:20163744-Algorithms,
pubmed-meshheading:20163744-Antineoplastic Agents,
pubmed-meshheading:20163744-Carcinoma, Renal Cell,
pubmed-meshheading:20163744-Female,
pubmed-meshheading:20163744-Humans,
pubmed-meshheading:20163744-Indoles,
pubmed-meshheading:20163744-Kidney Neoplasms,
pubmed-meshheading:20163744-Male,
pubmed-meshheading:20163744-Medical Oncology,
pubmed-meshheading:20163744-Middle Aged,
pubmed-meshheading:20163744-Prognosis,
pubmed-meshheading:20163744-Pyrroles,
pubmed-meshheading:20163744-Retrospective Studies,
pubmed-meshheading:20163744-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece. abamias@med.uoa.gr
|
|
pubmed:publicationType |
Journal Article
|
